• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, February 7, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Snake venom treatment investigated as antibiotic alternative for eye infections

Bioengineer by Bioengineer
July 18, 2018
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

An innovative University of Liverpool research project that will investigate whether compounds used to treat snake venom and bee stings could provide an alternative to antibiotics in treating eye infection has been awarded £170,000 by the charity Fight for Sight.

Professor Stephen Kaye and his team at the University's Department of Eye and Vision Science are investigating alternative treatments for microbial keratitis, an infection of the cornea that can be serious if not treated and may eventually cause sight loss.

They have found that the bacteria, Pseudomonas aeruginosa, which accounts for a third of all cases of this condition, produces toxins that are similar to those present in snake venom or bee stings.

Reducing damage to the eye

The researchers are now investigating whether anti-toxin treatments, called anti-phospholipases, can be delivered directly to the eye to limit or even prevent the cell damage caused by this condition.

Apart from the increase in antibiotic resistance, it is well established that antibiotics only have a limited effect in microbial keratitis. The aim of this study is to develop anti-P. aeruginosa agents as a non-antibiotic treatment for this condition, ultimately to reduce damage to the eye. Researchers hope this study will pave the way for a clinical trial to test a possible treatment.

Professor Kaye, who is also a Consultant Ophthalmologist at St Paul's Eye Unit based at the Royal Liverpool University Hospital, said: "We are grateful that Fight for Sight has agreed to support this project. We intend to investigate several promising anti-phospholipase agents, optimise their chemistry to increase penetration and minimise toxicity, as well as to design new agents. If successful these agents will be delivered topically to the eye in conjunction with other antimicrobials in cases of microbial keratitis."

Importance cannot be overstated

Fight for Sight is the leading UK charity dedicated to funding pioneering research to prevent sight loss and treat eye disease. Fight for Sight's overall research commitments currently amount to £8m for over 160 research projects at 49 different universities and hospitals across the UK.

Dr Neil Ebenezer, Director of Research, Policy and Innovation at Fight for Sight, said "The importance of this project cannot be overstated. Not only do antibiotics have limited impact on microbial keratitis but also antibiotic resistance is a growing threat to our current way of life. This study could also serve as a model for introduction of other non-antibiotic topical therapies for use in other bacterial infections of the eye. It is imperative that we find alternative solutions to ensure that patients continue to have access to effective treatments."

Microbial keratitis is an infection on the cornea, which is the clear window on the front of the eye. It can be a serious condition if not treated and can sometimes cause sight loss even with the correct treatment.

###

Media Contact

Simon Wood
[email protected]
44-151-794-8356
@livuninews

http://www.liv.ac.uk

Share12Tweet8Share2ShareShareShare2

Related Posts

Digital Health Perspectives from Baltic Sea Experts

February 7, 2026

Exploring Decision-Making in Dementia Caregivers’ Mobility

February 7, 2026

Succinate Receptor 1 Limits Blood Cell Formation, Leukemia

February 7, 2026

Palmitoylation of Tfr1 Drives Platelet Ferroptosis and Exacerbates Liver Damage in Heat Stroke

February 7, 2026
Please login to join discussion

POPULAR NEWS

  • Robotic Ureteral Reconstruction: A Novel Approach

    Robotic Ureteral Reconstruction: A Novel Approach

    82 shares
    Share 33 Tweet 21
  • Digital Privacy: Health Data Control in Incarceration

    63 shares
    Share 25 Tweet 16
  • Study Reveals Lipid Accumulation in ME/CFS Cells

    57 shares
    Share 23 Tweet 14
  • Breakthrough in RNA Research Accelerates Medical Innovations Timeline

    53 shares
    Share 21 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Digital Health Perspectives from Baltic Sea Experts

Florida Cane Toad: Complex Spread and Selective Evolution

Exploring Decision-Making in Dementia Caregivers’ Mobility

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 73 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.